[Jackie07]

Found it!

I wonder if the Weisenthal Group can get a grant from the government or financial backing from pioneers such as Craig Venter to conduct the phase II trial. Most clinical trials seems to be offered free to selected individuals.

But seems I remember some time ago I had located one research article on the particular method used here. I believe it reported a benefit of averaging 3 1/2 months surviving time. (7 months verses 3 1/2 months)

The Weisenthal Group ought to start a media campaign to draw attention and get needed funding and recruits.



Cell culture detection of microvascular cell death in clinical specimens of human neoplasms and peripheral blood
L. M. Weisenthal, N. Patel & C. Rueff-Weisenthal From the Weisenthal Cancer Group, Huntington Beach, CA, USA
Correspondence to Larry M. Weisenthal, Weisenthal Cancer Group, Huntington Beach, CA 92647, USA.
(fax: +714 596 2110; e-mail: mail@weisenthal.org).

Copyright © 2008 Blackwell Publishing Ltd

KEYWORDS
angiogenesis • cancer • cancer chemotherapy • cell biology • endothelial cells • oncology

Weisenthal LM, Patel N, Rueff-Weisenthal C (Weisenthal Cancer Group, Huntington Beach, CA, USA). Cell culture detection of microvascular cell death in clinical specimens of human neoplasms and peripheral blood. J Intern Med 2008; 264: 275–287.

ABSTRACT


Abstract. Background. Angiogenesis studies are limited by the clinical relevance of laboratory model systems. We developed a new method for measuring dead microvascular (MV) cells in clinical tissue, fluid and blood specimens, and applied this system to make several potentially novel observations relating to cancer pharmacology.
Methods. Dead MV cells tend to have a hyperchromatic, refractile quality, further enhanced during the process of staining with Fast Green and counterstaining with either haematoxylin–eosin or Wright–Giemsa. We used this system to quantify the relative degree of direct antitumour versus anti-MV effects of cisplatin, erlotinib, imatinib, sorafenib, sunitinib, gefitinib and bevacizumab.
Results. Bevacizumab had striking anti-MV effects and minimal antitumour effects; cisplatin had striking antitumour effects and minimal anti-MV effects. The `nib' drugs had mixed antitumour and anti-MV effects. Anti-MV effects of erlotinib and gefitinib were equal to those of sunitinib and sorafenib. There was no detectable VEGF in culture medium without cells; tumour cells secreted copious VEGF, reduced to undetectable levels by bevacizumab, greatly reduced by cytotoxic levels of cisplatin + anguidine, and variably reduced by DMSO and/or ethanol. We observed anti-MV additivity between bevacizumab and other drugs on an individual patient basis. Peripheral blood specimens had numerous MV cells which were strikingly visualized for quantification with public domain image analysis software using bevacizumab essentially as an imaging reagent.
Conclusions. This system could be adapted for simple, inexpensive and sensitive/specific detection of tissue and circulating MV cells in a variety of neoplastic and non-neoplastic conditions, and for drug development and individualized cancer treatment.